GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » Return-on-Tangible-Asset

ASKA Pharmaceutical Holdings Co (TSE:4886) Return-on-Tangible-Asset : 10.35% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ASKA Pharmaceutical Holdings Co's annualized Net Income for the quarter that ended in Dec. 2023 was 円9,316 Mil. ASKA Pharmaceutical Holdings Co's average total tangible assets for the quarter that ended in Dec. 2023 was 円89,991 Mil. Therefore, ASKA Pharmaceutical Holdings Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 10.35%.

The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset or its related term are showing as below:

TSE:4886' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.3   Med: 5.56   Max: 8.85
Current: 8.66

During the past 3 years, ASKA Pharmaceutical Holdings Co's highest Return-on-Tangible-Asset was 8.85%. The lowest was 5.30%. And the median was 5.56%.

TSE:4886's Return-on-Tangible-Asset is ranked better than
77.86% of 1084 companies
in the Drug Manufacturers industry
Industry Median: 1.745 vs TSE:4886: 8.66

ASKA Pharmaceutical Holdings Co Return-on-Tangible-Asset Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co Return-on-Tangible-Asset Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24
Return-on-Tangible-Asset
5.56 5.30 8.85

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 6.81 12.46 10.35 4.84

Competitive Comparison of ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset falls into.



ASKA Pharmaceutical Holdings Co Return-on-Tangible-Asset Calculation

ASKA Pharmaceutical Holdings Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=7545/( (82673+87868)/ 2 )
=7545/85270.5
=8.85 %

ASKA Pharmaceutical Holdings Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=9316/( (88305+91677)/ 2 )
=9316/89991
=10.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


ASKA Pharmaceutical Holdings Co  (TSE:4886) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


ASKA Pharmaceutical Holdings Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Traded in Other Exchanges
N/A
Address
2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines